Barinthus Biotherapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Barinthus Biotherapeutics plc income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Revenue & Gross Profit
Revenue14.970.8044.700.274.82
Cost of Revenue0.002.0142.3520.3714.39
Gross Profit14.970.802.35-20.10-9.57
Operating Expenses
Research & Development38.2544.8741.11-4.00-3.28
Selling, General & Administrative29.6739.846.3925.1210.48
Operating Expenses82.9484.7247.5021.127.20
Operating Income-67.97-83.91-2.80-41.22-16.77
Other Income/Expense
Interest Income2.682.883.100.000.00
Interest Expense0.050.030.02-2.67-3.60
Other Income/Expense6.74-1.080.576.332.08
Income
Income Before Tax-61.23-76.520.85-51.14-17.84
Income Tax Expense-0.04-3.08-4.47-0.030.10
Net Income-61.07-73.355.34-50.87-17.71
Net Income - Continuous Operations-61.07-73.455.32-51.110.00
Net Income - Discontinued Operations0.000.000.000.000.00
EBITDA-55.37-76.525.19-40.82-16.56
EBIT-61.23-76.520.87-41.22-16.77
Depreciation & Amortization5.802.304.320.400.21
Earnings Per Share
Basic EPS-2.00-2.00--2.00-2.00
Diluted EPS-2.00-2.00--2.00-2.00
Basic Shares Outstanding39.3538.3937.2525.897.90
Diluted Shares Outstanding39.3538.3938.1725.897.90